Journal of Medicinal Chemistry
Article
Mediates Motility and Metastasis. Proc. Natl. Acad. Sci. U. S. A. 1998,
95, 1441−14422. (d) Bean, J.; Brennan, C.; Shih, J.-Y.; Riely, G.; Viale,
A.; Wang, L.; Chitale, D.; Motoi, N.; Szoke, J.; Broderick, S.; Balak, M.;
Chang, W.-C.; Yu, C.-J.; Gazdarl, A.; Pass, H.; Rusch, V.; Gerald, W.;
Huang, S.-F.; Yang, P.-C.; Miller, V.; Ladanyi, M.; Yang, C.-H.; Pao, W.
MET Amplification Occurs With or Without T790M Mutations in
EGFR Mutant Lung Tumors with Acquired Resistance to Gefitinib or
Erlotinib. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 20932−20937. For
examples of Ron mutations or overexpression in human cancer, see
(e) Chen, Y. Q.; Zhou, Y. Q.; Angeloni, D.; Kurtz, A. L.; Qiang, X. Z.;
Wang, M. H. Overexpression and Activation of the RON Receptor
Tyrosine Kinase in a Panel of Human Colorectal Carcinoma Cell
Lines. Exp. Cell Res. 2000, 261, 229−238. (f) Zhou, Y. Q.; He, C.;
Chen, Y. Q.; Wang, D.; Wang, M. H. Altered Expression of the RON
Receptor Tyrosine Kinase in Primary Human Colorectal Adenocarci-
nomas: Generation of Different Splicing RON Variants and their
Oncogenic Potential. Oncogene 2003, 22, 186−197. (g) Bardella, C.;
Costa, B.; Maggiora, P.; Patane, S.; Olivero, M.; Ranzani, G. N.; De, B.
M.; Comoglio, P. M.; Di Renzo, M. F. Truncated RON Tyrosine
Kinase Drives Tumor Cell Progression and Abrogates Cell−Cell
Adhesion through E-Cadherin Transcriptional Repression. Cancer Res.
2004, 64, 5154−5161. (h) Zinser, G. M.; Leonis, M. A.; Toney, K.;
Pathrose, P.; Thobe, M.; Kader, S. A.; Peace, B. E.; Beauman, S. R.;
Collins, M. H.; Waltz, S. E. Mammary-Specific Ron Receptor
Overexpression Induces Highly Metastatic Mammary Tumors
Associated with Beta-Catenin Activation. Cancer Res. 2006, 66,
11967−11974.
(14) Cui, J. J.; McTigue, M.; Nambu, M.; Tran-Dube,
́
M.; Pairish, M.;
Shen, H.; Jia, L.; Cheng, H.; Hoffman, J.; Le, P.; Jalaie, M.; Goetz, G.
H.; Ryan, K.; Grodsky, N.; Deng, Y.-L.; Parker, M.; Timofeevski, S.;
Murray, B. W.; Yamazaki, S.; Aguirre, S.; Li, Q.; Zou, H.; Christensen,
J. Discovery of a Novel Class of Exquisitely Selective Mesenchymal−
Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and
Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmeth-
yl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol
(PF-04217903) for the Treatment of Cancer. J. Med. Chem. 2012, 55,
8091−8109.
(15) Bode, C. M.; Boezio, A. A.; Albrecht, B. K.; Bellon, S. F.; Berry,
L.; Broome, M. A.; Choquette, D.; Dussault, I.; Lewis, R. T.; Lin, M-
H.J.; Rex, K.; Whittington, D. A.; Yang, Y.; Harmange, J.-C. Discovery
and Optimization of a Potent and Selective Triazolopyridinone Series
of c-Met Inhibitors. Bioorg. Med. Chem. Lett. 2012, 22, 4089−4093.
(16) Cepero, V.; Sierra, J. R.; Corso, S.; Ghiso, E.; Casorzo, L.;
Perera, T.; Comoglio, P. M.; Giordano, S. MET and KRAS Gene
Amplification Mediates Acquired Resistance to MET Tyrosine Kinase
Inhibitors. Cancer Res. 2010, 70, 7580−7590.
(17) Munshi, N.; Jeay, S.; Li, Y.; Chen, C.-R.; France, D. S.; Ashwell,
M. A.; Hill, J.; Moussa, M. M.; Leggett, D. S.; Li, C. J. ARQ 197, a
Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine
Kinase with Antitumor Activity. Mol. Cancer Ther. 2010, 9, 1544−
1553.
(18) Katz, J. D.; Jewell, J. P.; Guerin, D. J.; Lim, J.; Dinsmore, C. J.;
Deshmukh, S. V.; Pan, B.-S.; Marshall, C. G.; Lu, W.; Altman, M. D.;
Dahlberg, W. K.; Davis, L.; Falcone, D.; Gabarda, A. E.; Hang, G.;
Hatch, H.; Holmes, R.; Kunii, K.; Lumb, K. J.; Lutterbach, B.;
Mathvink, R.; Nazef, N.; Patel, S. B.; Qu, X.; Reilly, J. F.; Rickert, K.
W.; Rosenstein, C.; Soisson, S. M.; Spencer, K. B.; Szewczak, A. A.;
Walker, D.; Wang, W.; Young, J.; Zeng, Q. Discovery of a 5H-
Benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) Inhibitor of c-
Met Kinase for the Treatment of Cancer. J. Med. Chem. 2011, 54,
4092−4108.
(19) (a) Kawatsura, M.; Hartwig, J. F. Simple, Highly Active
Palladium Catalysts for Ketone and Malonate Arylation: Dissecting the
Importance of Chelation and Steric Hindrance. J. Am. Chem. Soc. 1999,
121, 1473−1478. (b) Fox, J. M.; Huang, X.; Chieffi, A.; Buchwald, S. L.
Highly Active and Selective Catalysts for the Formation of α-Aryl
Ketones. J. Am. Chem. Soc. 2000, 122, 1360−1370. (c) Netherton, M.
R.; Fu, G. C. Air-Stable Trialkylphosphonium Salts: Simple, Practical,
and Versatile Replacements for Air-Sensitive Trialkylphosphines.
Applications in Stoichiometric and Catalytic Processes. Org. Lett.
2001, 3, 4295−4298.
(20) Grimm, J. B.; Katcher, M. H.; Witter, D. J.; Northrup, A. B. A
New Strategy for the Synthesis of Benzylic Sulfonamides: Palladium-
Catalyzed Arylation and Sulfonamide Metathesis. J. Org. Chem. 2007,
72, 8135−8138.
(21) (a) Mani, S.; Ghalib, M.; Chaudhary, I.; Goel, S. Alterations of
Chemotherapeutic Pharmacokinetic Profiles by Drug−Drug Inter-
actions. Expert Opin. Drug Metab. Toxicol. 2009, 5, 109−130.
(b) Mcleod, H. L. Clinically Relevant Drug−Drug Interactions in
Oncology. Br. J. Clin. Pharmacol. 1998, 45, 539−544.
(22) Kalgutkar, A. S.; Gardner, I.; Obach, R. S.; Shaffer, C. L.;
Callegari, E.; Henne, K. R.; Mutlib, A. E.; Dalvie, D. K.; Lee, J. S.;
Nakai, Y.; O’Donnell, J. P.; Boer, J.; Harriman, S. P. A Comprehensive
Listing of Bioactivation Pathways of Organic Functional Groups. Curr.
Drug Metab. 2005, 6, 161−225 and references therein.
(7) Follenzi, A.; Bakovic, S.; Gual, P.; Stella, M. C.; Longati, P.;
Comoglio, P. M. Cross-Talk Between the Proto-Oncogenes Met and
Ron. Oncogene 2000, 19, 3041−3049.
(8) Lee, W.-Y.; Chen, H. H. W.; Chow, N.-H.; Su, W.-C.; Lin, P.-W.;
Guo, H.-R. Prognostic Significance of Co-Expression of RON and
MET Receptors in Node-Negative Breast Cancer Patients. Clin. Cancer
Res. 2005, 11, 2222−2228.
(9) Cheng, H.-L.; Liu, H.-S.; Lin, Y.-J.; Chen, H. H-W.; Hsu, P.-Y.;
Chang, T.-Y.; Ho, C.-L.; Tzai, T.-S.; Chow, N.-H. Co-Expression of
RON and MET is a Prognostic Indicator for Patients with
Transitional-Cell Carcinoma of the Bladder. Br. J. Cancer 2005, 92,
1906−1914.
(10) Zou, H. Y.; Li, Q.; Lee, J. H.; Arango, M. E.; McDonnell, S. R.;
Yamazaki, S.; Koudriakova, T. B.; Alton, G.; Cui, J. J.; Kung, P.-P.;
Nambu, M. D.; Los, G.; Bender, S. L.; Mroczkowski, B.; Christensen, J.
G. An Orally Available Small-Molecule Inhibitor of c-Met, PF-
2341066, Exhibits Cytoreductive Antitumor Efficacy through Anti-
proliferative and Antiangiogenic Mechanisms. Cancer Res. 2007, 67,
4408−4417.
(11) (a) Qian, F.; Engst, S.; Yamaguchi, K.; Yu, P.; Won, K.-A.;
Mock, L.; Lou, T.; Tan, J.; Li, C.; Tam, D.; Lougheed, J.; Yakes, F. M.;
Bentzien, F.; Xu, W.; Zaks, T.; Wooster, R.; Greshock, J.; Joly, A. H.
Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-
2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF
Receptor Tyrosine Kinases. Cancer Res. 2009, 69, 8009−8016. (b) See
also a recent report of a more selective type II inhibitor: Liu, L.;
Norman, M. H.; Lee, M.; Xi, N.; Siegmund, A.; Boezio, A. A.; Booker,
S.; Choquette, D.; D’Angelo, N. D.; Germain, J.; Yang, K.; Yang, Y.;
Zhang, Y.; Bellon, S. F.; Whittington, D. A.; Harmange, J.-C.;
Dominguez, C.; Kim, T.-S.; Dussault, I. Structure-Based Design of
Novel Class II c-Met Inhibitors: 1. Identification of Pyrazolone-Based
Derivatives. J. Med. Chem. 2012, 55, 1858−1867.
(23) Signficantly, both 5a and 5g did not show significant inhibition
of CYP3A4 (<10%) at the zero minute time point as potent reversible
CYP3A4 inhibitors are not evaluable in this assay format.
(24) Pan, B.-S.; Chan, G. K. Y.; Chenard, M.; Chi, A.; Davis, L. J.;
Deshmukh, S. V.; Gibbs, J. B.; Gil, S.; Hang, G.; Hatch, H.; Jewell, J.
P.; Kariv, I.; Katz, J. D.; Kunii, K.; Lu, W.; Lutterbach, B. A.; Paweletz,
C. P.; Qu, X.; Reilly, J. F.; Szewczak, A. A.; Zeng, Q.; Kohl, N. E.;
Dinsmore, C. J. MK-2461, a Novel Multitargeted Kinase Inhibitor,
Preferentially Inhibits the Activated c-Met Receptor. Cancer Res. 2010,
70, 1524−1533.
(12) Lu, T.; Alexander, R.; Connors, R. W.; Cummings, M. D.;
Galemmo, R. A.; Hufnagel, H. R.; Johnson, D. L.; Khalil, E.; Leonard,
K. A.; Markotan, T. P.; Maroney, A. C.; Sechler, J. L.; Travins, J. M.;
Tuman, R. W. PCT Int. Appl. WO 2007075567, 2007.
(13) Schadt, O.; Bladt, F.; Blaukat, A.; Dorsch, D.; Friese-Hamim,
M.; Fittschen, C.; Graedler, U.; Meyring, M.; Rautenberg, W.; Stieber,
F.; Wilm, C. EMD 1214063, An Exquisitely Selective c-Met Kinase
Inhibitor in Clinical Phase 1. AACR 101st Annual Meeting,
Washington, DC, Apr 17−21, 2010; American Association for Cancer
Research: Washington, DC, 2010; Poster 5777.
2309
dx.doi.org/10.1021/jm301619u | J. Med. Chem. 2013, 56, 2294−2310